Ocular AI Partnerships CPI recently partnered with Bausch & Lomb to build and validate AI/ML models aimed at identifying oral drugs with eye delivery potential. This validates a repeatable, collaborative model with large pharma in a niche therapeutic area. Sales play: offer CPI’s AI platform and analytics services to ophthalmology-focused companies for ocular drug discovery, optimization, and safety profiling, with options to license models or engage in co-development.

Funding Pipeline CPI has secured NIEHS SBIR funding to advance AI tools like MegaTox and acetylcholinesterase reactivators, illustrating a successful government-funded R&D track record. This suggests a ready pathway for government-funded projects and partnerships with academic or federal contractors. Sales angle: target government agencies, research labs, and pharma clients seeking grant-backed R&D, offering CPI's MegaTox capabilities and AI drug discovery services, plus grant-readiness assistance.

Raleigh Expansion Expansion to Raleigh to house software development and operations signals scalable onshore capabilities and proximity to the US market. This presents opportunities to partner with local universities, CROs, and regional biotech clusters for collaboration, co-development, and talent augmentation. Sales approach: position CPI as a nearshore AI discovery partner, provide integration services, data pipelines, and co-sell with Raleigh-based tech and life sciences ecosystem.

AI Software CPI launched a commercial software product for predicting acetylcholinesterase inhibitors and has ongoing oncology AI collaborations. This shows a market-ready AI software offering that can be licensed or deployed as a service. Sales opportunities: license or subscription-based access to the AChE inhibitor predictor; explore cross-sell to oncology biotech firms for AI-assisted drug discovery, and leverage existing oncology partnerships to accelerate co-development deals.

Niche Focus Focused on rare and neglected diseases, CPI builds credibility with niche market players and grant-funded research programs. Coupled with its fee-for-services model, CPI can be an attractive partner for biotech companies seeking specialized AI-enabled discovery without a full internal AI team. Sales plan: target rare-disease biotechs, academic spin-outs, and consumer product firms needing safety/MEGAtox capabilities; offer tiered engagement models to match project scope and funding.